Correction of infantile agranulocytosis (Kostmann's syndrome) by allogeneic bone marrow transplantation

The American Journal of Medicine
J RappeportM J Chusid

Abstract

Allogeneic bone marrow transplantation has been unsuccessful as therapy for genetically determined bone marrow disorders. In patients prepared for transplantation with drugs alone long-term hematopoietic engraftment is not achieved due to the overgrowth of the infused donor bone marrow cells by residual recipient hematopoietic stem cells. Utilizing a combination of total body irradiation and antihuman thymocyte serum, the successful eradication of the abnormal hematopoietic stem cells of patients with the Wiskott-Aldrich syndrome and now infantile agranulocytosis has been achieved. Following preparation with total body irradiation and antihuman thymocyte serum a 20 month old patient with infantile agranulocytosis has complete donor hematopoietic and lymphoid engraftment one year after a histocompatible allogeneic bone marrow transplant. Prior to transplantation, this patient had no circulating or bone marrow granulocytes; following transplantation he has normal numbers of circulating granulocytes with normal in vivo and in vitro function. This therapeutic result demonstrates that genetic disorders of myeloid function can be corrected by allogeneic bone marrow transplantation following preparation with total body irradiation and...Continue Reading

References

Apr 24, 1975·The New England Journal of Medicine·E D ThomasC D Buckner
Mar 1, 1966·The Journal of Pediatrics·C E Krill, A M Mauer
Oct 1, 1970·Experimental Cell Research·T CasperssonC Johansson
Sep 1, 1960·Experimental Cell Research·P S MOORHEADD A HUNGERFORD

❮ Previous
Next ❯

Citations

Jan 1, 1990·Journal of Inherited Metabolic Disease·J R Hobbs
Jan 1, 1984·Springer Seminars in Immunopathology·R Parkman
Nov 21, 2007·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·C Zeidler, K Welte
Aug 21, 2013·Zeitschrift für Rheumatologie·C Zeidler
Jul 11, 2000·British Journal of Haematology·C ZeidlerK Welte
Apr 17, 2002·Seminars in Hematology·Cornelia Zeidler, Karl Welte
Jan 3, 1985·The New England Journal of Medicine·E D Thomas
Sep 29, 2005·Hematology·Cornelia Zeidler
Mar 7, 2002·Journal of Pediatric Hematology/oncology·A Banerjee, K M Shannon
Nov 30, 2006·Current Opinion in Hematology·Julia SkokowaKarl Welte
Dec 1, 1994·Archives of Disease in Childhood·I M Hann
May 21, 2011·Orphanet Journal of Rare Diseases·Jean DonadieuChristine Bellanné Chantelot
Jan 1, 1984·Cancer Investigation·K M Sullivan, R Storb
Apr 1, 1996·Annals of Medicine·W Friedrich
Jul 17, 2007·Seminars in Hematology·Cornelia Zeidler, Karl Welte
Aug 1, 1987·The American Journal of the Medical Sciences·R A Good
Mar 25, 2010·Pediatric Transplantation·Koichi OshimaUNKNOWN Hematopoietic Stem Cell Transplantation Committee of the Japanese Society of Pediatric Hematology
Dec 1, 1991·Pediatric Annals·R Parkman
Nov 13, 2010·Pediatric Blood & Cancer·G CarlssonH Hägglund
Jan 1, 1980·American Journal of Hematology·M J ChusidP A Tomasulo
Jun 1, 1993·American Journal of Hematology·W Y WongR K Brynes
Nov 19, 1990·The Medical Journal of Australia·M R VowelsR Brown
Oct 1, 1983·Clinics in Haematology·J M RappeportF S Rosen
Jun 1, 1996·Pediatric Clinics of North America·J C Bernini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.